Opportunistic infections in the cardiac transplant patient

Current Opinion in Cardiology

Volumn 11, Issue 2, 1996, Pages 191-203

  Thaler, Scott J ^a   Rubin, Robert H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPHOTERICIN; ANTIINFECTIVE AGENT; ATOVAQUONE; AZATHIOPRINE; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; LYMPHOCYTE ANTIBODY; MACROLIDE; MINOCYCLINE; NYSTATIN; PYRIMETHAMINE; RIFAMPICIN; SULFONAMIDE; TACROLIMUS;

COMMUNITY; CYTOMEGALOVIRUS; ENVIRONMENTAL PROTECTION; HEART SURGERY; HEART TRANSPLANTATION; HOSPITAL; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIOSIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK; TOXOPLASMOSIS; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; CROSS INFECTION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 0029930862     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199603000-00013     Document Type: Review

References (95)

1. Goldberg M, Berman E, Akman C: Homologous transplantation of the canine heart. J Int Coll Surg 1958, 30:575.
2. Lower R, Dong E, Shumway N: Long-term survival of cardiac homografts. Surgery 1965, 58:110.
3. Shumway S, Bolman R: Cardiac transplantation. In Surgery: Scientific Principles and Practice. Edited by Greenfield L, Mulholland M, Oldham K, Zelenock G. Philadelphia: JB Lippincott; 1993:541.
4. Kaye M: Registry of the International Society for Heart and Lung Transplantation: Tenth Official Report, 1993. J Heart Lung Tranplant 1993, 12:541.
5. Cooper J: Lung transplantation Curr Probl Surg 1989, 26:661.
6. Rubin RH: Infections in the organ transplant recipient. In Clinical Approach to Infection in the Compromised Host; edn 3. Edited by Rubin RH, Young LS. New York: Plenum Press; 1994:629.
7. Calhoon J, Nichols L, Davis R, Bryant CL, Levine SM, Zamora CA, Anzueta A, Lum CT, Grover FL, Trinkle JK: Single lung transplantation: factors in postoperative cytomegalovirus infection. J Thorac Cardiovasc Surg 1992, 103:21.
8. Kriett J, Smith C, Hayden A, Robert R, Parthasarathy R, Kapelanski DP, Jamieson SW: Lung transplantation without the use of antilymphocyte antibody preparations. J Heart Lung Transplant 1993, 14:915.
9. Hofflin J, Potasman I, Baldwin J, Oyer PE, Slinson EB, Remington JS: Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987, 106:209.
10. Rubin R, Cosimi A, Tolkoff-Rubin N, Russell PS, Hirsch MS: Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977, 24:458.
11. Chatterjee S, Fiala M, Weiner J, Stewart JA, Stacey B, Warner N: Primary cytomegalovirus and opportunistic infections: incidence in renal transplant recipients. JAMA 1978, 240:2446.
12. Rinaldo C, Carney W, Richter B, Black PH, Hirsch MS: Mechanisms of immunosuppression in cytomegalovirus mononucleosis. J Infect Dis 1980, 141:488.
13. Miller L, Naftel D, Bourge R, Kirklin JK, Brozena SC, Jarcho J, Hobbs RE, Mills RM: Infection after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 1994, 13:381.
14. McGiffin D, Galbraith A, McCarthy J, Tesar P: Mycotic false aneurysm of the aortic suture line after heart transplantation. J Heart Lung Transplant 1994, 13:926. This brief case report and review summarizes the reported microbiology of postoperative mycotic aneuryms and suggests that a combined surgical and medical approach is preferable in these patients.
15. Thompson D, Menkis A, Pflugfelder P: Mycotic aortic aneurysm after heart-lung transplantation. Transplantation 1989, 47:195.
16. Dowling R, Baladi N, Zenati M, Dummer JS, Kormos RL, Armitage JM, Yousem SA, Hardesty RL, Griffith BP: Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg 1990, 49:118.
17. Slater A, Ganzel B, Keller M, Tobin GR, Gray LA: Repair of infected pseudoaneurysm with aortic arch replacement after orthotopic heart transplantation. J Heart Transplant 1990, 9:230.
18. Palac R, Strausbaugh L, Antonovic R, Floten H.: An unusual complication of cardiac transplantation: infected aortic pseudaneurysm. Ann Thorac Surg 1991, 51:479.
19. Anthuber M, Kemkes B, Kreuzer E, Gokel M, Schuetz A, Kugler C, Sudhoff F: Mediastinitis and mycotic aneurysm of the aorta. Tex Heart Inst J 1991, 18:186.
20. Schulman L, Reison D, Austin J, Rose EA: Cytomegalovirus pneumonitis after cardiac transplantation. Arch Intern Med 1991, 151:1118.
21. Duncan S, Cook D: Survival of ganciclovir-treated heart transplant recipients with cytomegalovirus pneumonitis. Transplantation 1991, 52:910.
22. Arabia F, Rosado L, Huston C, Sethi GK, Copeland JG: Incidence and recurrence of gastrointestinal cytomegalovirus infection in heart transplantation. Ann Thorac Surg 1993, 55:8.
23. Bramwell N, Davies R, Koshal A, Tse GNW, Keon WJ, Walley VM: Fatal gastrointestinal hemorrhage caused by cytomegalovirus duodenitis and ulceration after heart transplantation. J Heart Transplant 1987, 6:303.
24. Escudero-Fabre A, Cummings O, Kirklin J, Bourge RC, Aldrete JS: Cytomegalovirus colitis presenting as hematochezia and requiring resection. Arch Surg 1992, 127:102.
25. Gonwa T, Capehart J, Pilcher J, Alivizatos PA: Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient. Transplantation 1989, 47:197.
26. Grattan M, Moreno-Cabral C, Starnes V, Oyer PE, Stinson EB, Shumway NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561.
27. Everett J, Hershberger R, Norman D, Chou S, Ratkovec RM, Cobanoglu A, Ott GY, Hosenpud JD: Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 1992, 11:S133-S137.
28. McDonald K, Rector T, Braunlin E, Kubo SH, Olivari MT: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol 1989, 64:359.
29. Loebe M, Schuler S, Zais O, Warnecke H, Fleck E, Hetzer R: Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant 1990, 9:707.
30. Kendall T, Wilson J, Radio S, Kandolf R, Gulizia JM, Winters GL, Costanzo-Nordin, MR, Malcom GT, Thieszen SL, Miller LW, McManus BM: Cytomegalovirus and other herpesviruses: do they have a role in the development of accelerated coronary arterial disease in human heart allografts? J Heart Lung Transplant 1992, 11:S14.
31. Normann S, Salomon D, Leelachaikul P, Khan SR, Staples ED, Alexander JA, Mayfield WR, Knauf DG, Sadler LA, Selman S: Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cytomegalovirus infection. J Heart Lung Transplant 1991, 10:674.
32. Lemstrom K, Aho P, Bruggeman C, Hayry P: Cytomegalovirus infection enhances mRNA expression of platelet-derived growth factor-BB and transforming growth factor β1 in rat aortic allografts: possible mechanism for cytomegalovirus-enhanced graft atherosclerosis. Arterioscler Thromb 1994, 14:2043. Using a rat model of (heterotopic) aortic transplantation, the authors demonstrate that in allograft aortas similar changes occur as would be expected in human allograft atherosclerosis, including adventitial inflammation and intimai thickening. No such changes even with cytomegalovirus infection occur in syngeneic transplants. There is upregulation in several growth factors that are implicated in altering intimai thickness and regulating smooth muscle cells of the aorta.
33. Lemstrom K, Bruning J, Bruggeman C, Koskinen P, Aho PT, Yilmaz S, Lautenschlager IT, Hayry PJ: Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation 1994, 90:1969. In the same rat aortic transplantation model, the authors began ganciclovir treatment either 1 day prior to cytomegalovirus infection (prophylaxis group) or at day 7 or later (treatment group) and continue treatment for 14 days. Rats in the prophylaxis group had a significant reduction in inflammatory cell proliferation in the adventitia and intima and a reduction in interleukin-2 receptor positive cells. The authors also demonstrated an effect of ganciclovir on the proliferative responses of even uninfected smooth muscle cells that is still under investigation.
34. Koskinen P, Nieminen M, Mattila S, Hayray PJ, Lautenschlager IT: The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 1993, 55:547.
35. Van der Bij W, Van Dijk R, Van Son W, Toresma R, Prenger KB, Prop J, Tegzess AM, The TH: Antigen test for early diagnosis of active cytomegalovirus infection in heart transplant recipients. J Heart Transplant 1988, 7:106.
36. Gerna G, Zipeto D, Parea M, Revello MG, Silini E, Percivalle E, Zavattoni M, Grossi P, Milanesi G: Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia and DNAemia. J Infect Dis 1991, 164:488.
37. Egan J, Barber L, Lomax J, Fox A, Yonan N, Rahman AN, Campbell CS, Deiraniya AK, Carroll KB, Craske J, Turner A, Woodcock AA: Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995, 50:9. A prospective study on 23 heart transplant and nine lung transplant recipients using weekly surveillance for antigenemia using a mouse monoclonal anticytomegalovirus antibody with more than 50 positive polymorphonuclear leukocytes per 200,000 cells defined as high positive. This test was able to accurately predict symptomatic cytomegalovirus syndrome or invasive disease and became positive significantly before the onset of symptoms.
38. Merigan T, Renlund D, Keay S, Bristow MR, Starnes V, O'Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM et al.: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992, 326:1182.
39. MacDonald P, Keogh A, Marshman D, Richens D, Harvison A, Kaan AM, Spratt PM: A double-blind placebo-controlled trial fo low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant 1995, 14:32. A randomized study of ganciclovir 5 mg/kg three times weekly vs placebo for 6 weeks in 52 patients at one center. In contrast to a prior study using ganciclovir for 28 days, here no benefit was seen in the larger cytomegalovirus seropositive recipient group whereas benefit was seen in the high-risk seropositive donor - seronegative recipient group. The absence of OKT3 induction perhaps explains the relatively low incidence of cytomegalovirus in the seropositive recipient placebo group (about 25%).
40. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss H, Rubin RH: Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992, 53:68.
41. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Snydman DR, Freeman R, Lorber MI, Rubin RH: Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients; a randomized controlled trial Ann Intern Med 1995, 123:18. A randomized controlled, multicenter trial that demonstrated that as little as 2.5 mg/kg/d of intravenous ganciclovir during antilymphocyte antibody therapy significantly decreased the incidence of cytomegalovirus disease. Since the completion of this study, this approach has been found to be equally effective in cardiac allograft recipients at a slightly higher dose of 5 mg/kg/d.
42. Chang R, Lewis J, Reynolds R, Sullivan MJ, Neuman J: Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann Intern Med 1978, 88:34.
43. Nalesnik M, Jaffa R, Starzl T, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J: The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A - prednisone Immunosuppression. Am J Pathol 1988, 133:173.
44. Morrison V, Dunn D, Manivel C, Gajl-Peczalska KJ, Peterson BA: Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994, 97:14.
45. Pirsch J, Stratta R, Sollinger H, Hafez GR, D'Allessandro AM, Kalayoglu M, Belzer FO: Treatment of severe Epstein-Barr virus - induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989, 86:241.
46. Hanto D, Frizzera G, Gajl-Peczalska K, Balfour HH, Simmons RL, Najarian JS: Acyclovir therapy for Epstein-Barr virus-induced posttransplant lymphoproliferative diseases. Transplant Proc 1985, 27:89.
47. Walker R, Paya C, Marshall W, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CGA: Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung and other solid organ transplantations. J Heart Lung Transplant 1995, 14:214. This study represents a large retrospective review of the Mayo Clinic experience with 288 liver, 44 heart, 20 lung, and 37 kidney-pancreas transplant recipients from 1985 to present. Fourteen adult cases of PTLD were diagnosed during the time period. Only three of 367 patients seropositive for EBV developed PTLD versus 11 of 22 patients seronegative for EBV pretransplantation who developed PTLD; most of these 11 patients seroconverted posttransplantation. Disease tended to occur within the first 2 years after transplantation; localized disease to the allograft or to nodes was far more responsive to therapy than extranodal disease or CNS disease.
48. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE: The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988, 45:719.
49. Krick J, Remington J: Toxoplasmosis in the adult; an overview N Engl J Med 1987, 298:550.
50. Hirsch R, Burke B, Kersey J: Toxoplasmosis in bone marrow transplant recipients. J Pediatr 1984, 105:426.
51. Hagensee M, Bauwens J, Kjos B, Bowden R: Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994, 19:402.
52. Mayes J, O'Connor B, Avery R, Castellani W, Carey W: Transmission of Toxoplasma gondii infection by liver transplantation. Clin Infect Dis 1995, 21:511.
53. Wagner F, Reichenspurner H, Uberfuhr P, Weiss M, Fingerle V, Reichart B: Toxoplasmosis after heart transplantation: diagnosis by endomyocardial biopsy. J Heart Lung Transplant 1994, 3:916. In this brief case report, the patient, who was treated with steroids, developed acute rejection on day 10. Several days later an fever of undetermined origin syndrome developed that culminated on day 33 with a new pencardial effusion. Endomyocardial biopsy confirmed T. gondii infection, which responded to therapy. The importance of biopsy to make the diagnosis in this case is reviewed.
54. McGregor C, Fleck D, Nagington J, Stovin PGI, Cory-Pearce R, English TAH: Disseminated toxoplasmosis in cardiac transplantation. J Clin Pathol 1984, 37:74.
55. Wreghitt T, Haklim M, Gray J, Balfour AH, Stovin PGI, Stewart S, Scott J, English TAH, Wallwork J: Toxoplasmosis in heart and heart and lung transplant recipients. J Clin Pathol 1989, 42:194.
56. Luft B, Naot Y, Araujo F, Stinson EB, Remington JS: Primary and reactivated toxoplasma infection in patients with cardiac transplants. Ann Intern Med 1983, 99:27.
57. Lichtenstein I. MacGregor R: Mycobacterial infections in renal transplant recipients: reports of five cases and review of the literature. Rev Infect Dis 1983, 5:216.
58. Malhotra K, Dash S, Dhawan I, Bhuyan UN, Gupta A: Tuberculosis and renal infections-observations from an endemic area of tuberculosis. Postgrad Med J 1986, 62:359.
59. Munoz P, Palomo J, Munoz R, Rodriguez-Creixems M, Pelaez T, Bouza E: Tuberculosis in heart transplant recipients. Clin Infect Dis 1995, 21:398.
60. Spence R, Dafoe D, Rabin G, Grossman RA, Naji A, Barker CF, Perloff LJ: Mycobacterial infections in renal allograft recipients. Arch Surg 1983, 118:356.
61. Patel R, Roberts G, Keating M, Paya CV: Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263.
62. Novick R, Moreno-Cabral C, Stinson E, Oyer PE, Starnes VA, Hunt SA, Shumway NE: Nontuberculous mycobacterial infections in heart transplant recipients: a seventeen-year experience. J Heart Transplant 1990, 9:357.
63. Tebas P, Sultan F, Wallace R: Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995, 20:443.
64. Trulock E, Bolman R, Genton R: Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis. Am Rev Respir Dis 1989, 140:802.
65. LeMense G, VanBakel A, Crumbley A, Judson M: Mycobacterium scrofulaceum zinfection presenting as lung nodules in a heart transplant recipient. Chest 1994, 106:1918.ZZZ In this brief case report, the authors discuss the causes of pulmonary nodules in heart transplant recipients, most commonly, Aspergillus and Nocardia spp and present this case as the first published case of atypical mycobacteria in a heart transplant recipient causing pulmonary nodules. The importance of reduced corticosteroids as an important factor in fewer cases of typical and atypical mycobacteria among transplant recipients is discussed.
66. Askgaard D, Wilcke T, Dossing M: Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Thorax 1995, 50:213. The authors present a case report of a woman with significant hepatitis from the combination of both isoniazid and rifampin and briefly discuss the role of rifampin in altering the metabolism of isoniazid into the hepatotoxic hydrazine pathway.
67. Gersema L, Porter C, Russell E: Suspected drug Interaction between cyclosporine and clarithromycin [letter]. J Heart Lung Transplant 1994, 13:343. The authors discuss a potential role for clarithromycin in inhibiting the normal cytochrome P450 metabolism of cyclosporine, as is the case for erythromycin. They postulate the affinity of clarithromycin for the enzyme is lower and predict less of an interaction.
68. Paya C: Fungal infection in solid-organ transplantation. Clin Infect Dis 1993, 16:677.
69. Hibberd P, Rubin P: Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994, 19:S33-S40.
70. Mayor J, Nimer L, Carroll K: Isolated pulmonary Aspergilar infection in cardiac transplant recipients: case report and review. Clin Infect Dis 1992, 15:698.
71. Gurwith M, Stinson E, Remington J: Aspergillus infection complicating cardiac transplantation. Arch Intern Med 1971, 128:541.
72. Bly B, Jacobs F, Antoine M, depierreux M, Serruys E, Primo G, Thys JP: Mediastinitis caused by Aspergillus fumigatus with ruptured aortic pseudoaneurysm in a heart transplant recipient: case study. Heart Lung 1993, 22:145.
73. Loria K, Salinger M, Frohlich T, Gengelman MD, Cook FV, Arentzen CE: Primary cutaneous aspergillosis in a heart transplant recipient treated with surgical excision and oral itraconazole. J Heart Lung Transplant 1992, 11:156.
74. Hall W, Martinez A, Dummer J, Griffith BP, Hardesty RL, Bahnson HT, Lunsford LD: Central nervous system infections in heart and heart-lung transplant recipients. Arch Neurol 1989, 46:173.
75. Massin E, Zeluff B, Carrol C, Radovancevic B, Benjamin RS, Ewer MS, Bransford TL, Buja LM: Cardiac transplantation and aspergillosis. Circulation 1994, 90:1552. The authors present in clinicopathologic conference format a young woman 1 to 2 years after heart transplantation who developed chronic headaches and on computed tomography scan has multiple CNS lesions. Aspergillosis infection is briefly reviewed.
76. Hadley S, Karchmer AW: Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995, 9:1045. The authors present a complete review of the epidemiology, pathogenesis, and clinical management (both prevention and treatment) of fungal infection in the organ transplant patient.
77. Wolfson JS, Sober AJ, Rubin RH: Dermatologic manifestations of infection in immunocompromised patients. Medicine 1985, 64:115.
78. Fishman JA: Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995, 9:1005. A complete review of all aspects of pneumocystosis and parasitic infections in transplant recipients.
79. Ware R: Human Parvovirus infection J Pediatr 1989, 114:343.
80. Neild G, Anderson M, Hawes S, Colvin B: Parvovirus infection after renal transplant [letter]. Lancet 1986, li:1226.
81. Corral D, Darras F, Jensen C, Hakala TR, Naides SJ, Krause JR, Starzl TE, Jordan ML: Parvovirus B19 infection causing pure red cell aplasia in a recipient of pediatric donor kidneys. Transplantation 1993, 55:427.
82. Nour B, Green M, Michaels M, Reyes J, Tzakis A, Gartner JC, McLoughlin L, Starzl TE: Parvovirus B19 infection in pediatric transplant patients. Transplantation 1993, 56:835.
83. Janner D, Bork J, Baum M, Chinnock R: Severe pneumonia after heart transplantation as a result of human parvovirus B19. J Heart Lung Transplant 1994, 13:336. The authors report the first case of parvovirus B19 - induced pneumonitis in a pediatric heart transplant recipient. The patient developed rash, fever, and infiltrates 2 weeks postoperatively; BAL was negative for other pathogens and IgM against parvovirus B19 was positive. No parvovirus B19 DNA was isolated, however.
84. Zenati M, Milano A, Livi U, Cattelan A, Casarotto D: Successful treatment of disseminated infection with Listeria monocytogenes in a heart transplant recipient. J Heart Lung Transplant 1994, 13:345. A case of listeria meningitis associated with marked hypoglycorrhachia is described in a 52-year-old man 150 days after transplantation associated with concurrent cytomegalovirus syndrome.
85. Lamer A, Conway M, Mitchell R, Forfar J: Recurrent Listeria monocytogenes meningitis in a heart transplant recipient. J Infect 1989, 19:263.
86. Stamm A, Smith S, Kirklin J, McGifin D: Listerial myocarditis in cardiac transplantation. Rev Infect Dis 1990, 12:820.
87. Arduino R, Johnson P, Miranda A: Nocardiosis in renal transplant recipients undergoing immunosuppression with cyclosporine. Clin Infect Dis 1993, 16:505.
88. Krick J, Stinson E, Remington J: Nocardia infection in heart transplant patients. Ann Intern Med 1975, 82:18.
89. Ostrum R: Nocardia septic arthritis of the hip with associated avascular necrosis: a case report. Clin Orthop 1993, 288:282.
90. Thaler F, Gotainer B, Teodori G, Dubois C, Loirat PH: Mediastinitis due to Nocardia asteroides after cardiac transplantation. Intensive Care Med 1992, 18:127.
91. Rees W, Schuler S, Hummel M, Hempel S, Moller JH, Hetzer R: Primary cutaneous Nocardia farcinica infection after heart transplantation: a case report. J Thorac Cardiovasc Surg 1995, 109:181. Although the vast majority of nocardiosis is pulmonary with or without metastatic spread to other sites, especially the CNS, the authors of this case report present a locally invasive case related to the intramuscular injection of pain medications. This also represents the first case of N. farcinica infection in a transplant patient, the majority of which are due to N. asteroides or N. brasiliensis.
92. Rubin RH: Preemptive therapy in immunocompromised hosts. N Engl J Med 1991, 324:1057.
93. Rubin RH, Tolkoff-Rubin NE: Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993, 37:619.
94. DeVault GA, King JW, Rohr MS: Opportunistic infection with Strongyloides stercoralis in renal transplantation. Rev Infect Dis 1990, 12:653.
95. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CGA, Paya CV: Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995, 20:1346-1353.